Latanoprost

Catalog No.S4709 Batch:S470904

Technical Data

Formula

C₂₆H₄₀O₅

Molecular Weight

432.59

CAS No.

130209-82-4

Solubility (25°C)*

In vitro

DMSO

87 mg/mL (201.11 mM)

Ethanol

87 mg/mL (201.11 mM)

Water

Insoluble

In vivo (Add solvents to the product individually and in order)

Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O	4.35mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 87 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% corn oil	4.35mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 87 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Latanoprost (Xalatan, PhXA41) is a prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect. Latanoprost increases uveoscleral outflow and thereby reduces intraocular pressure.

Targets

retinoid X receptor α ^[2]

PGF-prostanoid receptor ^[3]

In vitro

Latanoprost functioned as both an indirect activator of AMP-activated protein kinase and a selective retinoid X receptor α (RXRα) antagonist able to selectively antagonise the transcription of a RXRα/peroxisome proliferator-activated receptor γ heterodimer^[2]. Latanoprost induced morphological abnormality and viability decline of HCS cells in vitro. It induces cell cycle arrest of HCS cells. Latanoprost induces abnormal changes of plasma membrane, DNA fragmentation and ultrastructural abnormality of HCS cells. Caspase activation in HCS cells is also activated by Latanoprost treatment. Latanoprost induces MTP disruption and quantitative changes of mitochondrion-associated pro-apoptotic regulators in HCS cells^[1]. Latanoprost is effective in inhibiting adipogenesis, reducing lipogenesis, promoting fatty acid oxidation and enhancing GLUT4 translocation and glucose uptake both in adipocytes and myotubes^[2].

In vivo

Latanoprost, a clinical drug for treating primary open-angle glaucoma and intraocular hypertension, effectively ameliorates glucose and lipid disorders in two mouse models of type 2 diabetes. Its treatment improves glucose tolerance. Chronic administration of latanoprost decreases serum lipids and enhances insulin signalling in white adipose tissue and skeletal muscle. It effectually activates AMPK and regulates glucose and lipid metabolism-relevant genes in diabetic mice^[2].

Density

1.093 g/mL

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines Human corneal stromal (HCS) cells Concentrations from 50 mg/l to 0.78125 mg/l Incubation Time 4, 8, 12 h Method HCS cells were inoculated into a 24-well culture plate (Nunc) and cultured in 10% FBS-DMEM/F12 medium at 37°C in a humidified 5% CO2 incubator. After the cells grew into logarithmic phase, the culture medium of each culture plate well was replaced entirely with the medium containing latanoprost at concentrations varying from 50 mg/l to 0.78125 mg/l, respectively. The cells were cultured under the same condition as described earlier, and their morphology and growth status were monitored every 4 h under an Eclipse TS100 inverted microscope.
Animal Study:^{^[2]}	Animal Models db/db or ob/ob mice Dosages 10 or 40 mg/kg Administration i.p.

Cell Assay:^{^[1]}

Cell lines
Human corneal stromal (HCS) cells
Concentrations
from 50 mg/l to 0.78125 mg/l
Incubation Time
4, 8, 12 h
Method
HCS cells were inoculated into a 24-well culture plate (Nunc) and cultured in 10% FBS-DMEM/F12 medium at 37°C in a humidified 5% CO2 incubator. After the cells grew into logarithmic phase, the culture medium of each culture plate well was replaced entirely with the medium containing latanoprost at concentrations varying from 50 mg/l to 0.78125 mg/l, respectively. The cells were cultured under the same condition as described earlier, and their morphology and growth status were monitored every 4 h under an Eclipse TS100 inverted microscope.

Animal Study:^{^[2]}

Animal Models
db/db or ob/ob mice
Dosages
10 or 40 mg/kg
Administration
i.p.

References

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.